Screener
MapLight Therapeutics, Inc. MPLT Chemistry Manufacturing And Controls Expenses — Research And Development Expense
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: MapLight Therapeutics, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:25 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-224129
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Clinical trial expenses | $24,819 | $1,939 |
| Employee-related research and development expenses | 15,993 | 7,050 |
| Chemistry, manufacturing and controls expenses | 6,417 | 3,956 |
| Preclinical program expenses | 5,522 | 6,081 |
| Other research and development expenses | 933 | 761 |
| Employee-related general and administrative expenses | 6,990 | 2,060 |
| Professional fees and other general and administrative expenses | 3,829 | 1,696 |
| Other segment items(1) | (3,835) | (1,203) |
Item 1. Financial Statements.
FAQ
- What is MapLight Therapeutics, Inc.'s chemistry manufacturing and controls expenses — research and development expense?
- MapLight Therapeutics, Inc. (MPLT) reported chemistry manufacturing and controls expenses — research and development expense of $6.42M in Q1 2026.
- How has MapLight Therapeutics, Inc.'s chemistry manufacturing and controls expenses — research and development expense changed year-over-year?
- MapLight Therapeutics, Inc.'s chemistry manufacturing and controls expenses — research and development expense increased by 62.2% year-over-year, from $3.96M to $6.42M.
- What does chemistry manufacturing and controls expenses — research and development expense mean?
- This metric represents the portion of total research and development expenditures specifically allocated to chemistry, manufacturing, and controls (CMC) activities. It captures the costs associated with developing, scaling, and validating the manufacturing processes required to produce clinical-grade drug candidates. Monitoring these expenses provides insight into the company's investment in process optimization and supply chain readiness for its therapeutic pipeline.
Ask your AI about MapLight Therapeutics, Inc.'s chemistry manufacturing and controls expenses — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude